Study of VT30-101 in Subjects with PIK3CA or TEK-related Venous, Lymphatic or Mixed Malformations (VT-30)
This is an open-label, repeat-application, intra-subject, dose escalation (Part 1) followed by a randomized, double-blind, placebo-controlled (Part 2) trial of topical VT30 in subjects with venous, lymphatic or mixed malformations associated with PIK3CA or TEK genetic mutations.
Ages eligible for study: 18 - 60 years old (Part 1); 16 - 60 years old (Part 2)
Sexes eligible for study: All
Detailed inclusion and exclusion criteria as listed on clinicaltrials.gov